| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. | Br J Haematol | 2004 | 3.49 |
| 2 | Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. | Leukemia | 2008 | 1.46 |